JPRN-UMIN000007188已完成未知
Maitenance therapy with bortezomib for multiple myeloma after autologus stem cell transplantation - Maitenance therapy with bortezomib for multiple myeloma after autologus stem cell transplantation
niversity Of Tokyo Hospital, Department of Hematology and Oncology0 个研究点目标入组 20 人开始时间: 2012年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Allergy for Bortezomib, mannitol, and boron. 2. A woman during pregnancy or potential pregnancy. 3. Patients who cannot stop drugs or therapy restricted in this trial. 4. Patients who are recoginized as inadaptable for this trial.
研究者
相似试验
已完成
不适用
Phase II study of bortezomib maintenance therapy for multiple myeloma patientsMultiple MyelomaJPRN-UMIN000013912ational Hospital Organization Disaster Medical Center of Japan96
招募中
不适用
Bortezomib maintenance therapy in newly diagnosed patients with mantle cell lymphoma, responsive on rituximab combined with CHOP and high dose Ara-C and after BEAM with auto PSCT rescue.MCL (WHO classification)Ann Arbor stage II ¨C IV CD20 positiveNL-OMON24708Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl90
进行中（未招募）
不适用
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patientsEUCTR2008-004822-17-NLniversity Medical Center
已完成
2 期
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patientsM. Kahler.10018849Multiple myelomaNL-OMON38293niversitair Medisch Centrum Groningen73
进行中（未招募）
不适用
Bortezomib as consolidation therapy in patients aged 60 years and younger with multiple myelomamultiple myeloma in patients aged 60 years and younger having been treated before initiation of the study with a high dosage chemotherapy with melphalane followed by an autologous or allogenic stemcell transplantationMedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-004948-31-DEJANSSEN-CILAG GmbH